

# Irene Lambrinouadaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7893389/publications.pdf>

Version: 2024-02-01

283  
papers

7,111  
citations

57758

44  
h-index

106344

65  
g-index

285  
all docs

285  
docs citations

285  
times ranked

8152  
citing authors

#	ARTICLE	IF	CITATIONS
1	Menopause. Nature Reviews Disease Primers, 2015, 1, 15004.	30.5	288
2	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine, 2020, 67, 1-8.	2.3	150
3	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4660-4666.	3.6	147
4	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal, 2021, 42, 967-984.	2.2	136
5	EMAS position statement: Managing women with premature ovarian failure. Maturitas, 2010, 67, 91-93.	2.4	128
6	Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Archives of Gynecology and Obstetrics, 2012, 286, 99-103.	1.7	113
7	Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. European Journal of Endocrinology, 2019, 180, 41-50.	3.7	109
8	Pathogenesis of endometriosis: The role of defective "immunosurveillance"™. European Journal of Contraception and Reproductive Health Care, 2007, 12, 194-202.	1.5	107
9	Cross-sectional long-term micronutrient deficiencies after sleeve gastrectomy versus Roux-en-Y gastric bypass: A pilot study. Surgery for Obesity and Related Diseases, 2014, 10, 262-268.	1.2	106
10	Measurable serum markers of oxidative stress response in women with endometriosis. Fertility and Sterility, 2009, 91, 46-50.	1.0	100
11	Prolactin and Preclinical Atherosclerosis in Menopausal Women With Cardiovascular Risk Factors. Hypertension, 2009, 54, 98-105.	2.7	95
12	EMAS position statement: Vitamin D and postmenopausal health. Maturitas, 2012, 71, 83-88.	2.4	95
13	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101, 23-30.	2.4	94
14	Menopause and diabetes: EMAS clinical guide. Maturitas, 2018, 117, 6-10.	2.4	91
15	Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas, 2018, 107, 7-12.	2.4	88
16	The role of the oxidative-stress in the endometriosis-related infertility. Gynecological Endocrinology, 2009, 25, 75-81.	1.7	87
17	EMAS position statement: Management of uterine fibroids. Maturitas, 2014, 79, 106-116.	2.4	85
18	The TyG Index as a Marker of Subclinical Atherosclerosis and Arterial Stiffness in Lean and Overweight Postmenopausal Women. Heart Lung and Circulation, 2018, 27, 716-724.	0.4	85

#	ARTICLE	IF	CITATIONS
19	EMAS position statement: Predictors of premature and early natural menopause. <i>Maturitas</i> , 2019, 123, 82-88.	2.4	80
20	Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 193-201.	3.4	78
21	Connected health and integrated care: Toward new models for chronic disease management. <i>Maturitas</i> , 2015, 82, 22-27.	2.4	77
22	EMAS position statement: The ten point guide to the integral management of menopausal health. <i>Maturitas</i> , 2015, 81, 88-92.	2.4	76
23	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. <i>Osteoporosis International</i> , 2020, 31, 2271-2286.	3.1	76
24	Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. <i>European Journal of Endocrinology</i> , 2006, 154, 907-916.	3.7	75
25	Thoracic Endometriosis Syndrome. <i>Respiration</i> , 2008, 75, 113-119.	2.6	73
26	MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview. <i>European Journal of Endocrinology</i> , 2017, 176, R283-R308.	3.7	72
27	EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. <i>Maturitas</i> , 2015, 81, 410-413.	2.4	70
28	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). <i>Maturitas</i> , 2016, 89, 63-72.	2.4	67
29	Menopause: a cardiometabolic transition. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 442-456.	11.4	64
30	EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy. <i>Maturitas</i> , 2012, 73, 171-174.	2.4	63
31	Association between age at menopause and fracture risk: a systematic review and meta-analysis. <i>Endocrine</i> , 2019, 63, 213-224.	2.3	61
32	Bisphosphonates. <i>Annals of the New York Academy of Sciences</i> , 2006, 1092, 397-402.	3.8	59
33	Previous Gestational Diabetes Mellitus and Markers of Cardiovascular Risk. <i>International Journal of Endocrinology</i> , 2012, 2012, 1-6.	1.5	59
34	Genetics in Gestational Diabetes Mellitus: Association with Incidence, Severity, Pregnancy Outcome and Response to Treatment. <i>Current Diabetes Reviews</i> , 2010, 6, 393-399.	1.3	56
35	Sarcopenia in post-menopausal women: Is there any role for vitamin D?. <i>Maturitas</i> , 2015, 82, 56-64.	2.4	55
36	The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. <i>Maturitas</i> , 2017, 99, 27-36.	2.4	54

#	ARTICLE	IF	CITATIONS
37	Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. <i>Current Vascular Pharmacology</i> , 2019, 17, 564-572.	1.7	54
38	EMAS position statement: Testosterone replacement therapy in the aging male. <i>Maturitas</i> , 2016, 84, 94-99.	2.4	53
39	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. <i>Maturitas</i> , 2020, 135, 82-88.	2.4	51
40	Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 445-451.	2.9	50
41	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Climacteric</i> , 2019, 22, 429-434.	2.4	50
42	EMAS position statement: Managing the menopause in the context of coronary heart disease. <i>Maturitas</i> , 2011, 68, 94-97.	2.4	49
43	Elevated placental growth factor concentrations at 11-14 weeks of gestation to predict gestational diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1419-1425.	3.4	49
44	Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. <i>Endocrine</i> , 2021, 74, 478-497.	2.3	49
45	EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women. <i>Maturitas</i> , 2013, 75, 181-190.	2.4	46
46	EMAS position statement: Managing obese postmenopausal women. <i>Maturitas</i> , 2010, 66, 323-326.	2.4	45
47	Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. <i>Maturitas</i> , 2011, 68, 13-16.	2.4	45
48	Eating habits and behaviors of older people: Where are we now and where should we go?. <i>Maturitas</i> , 2018, 114, 14-21.	2.4	44
49	Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. <i>Menopause</i> , 2021, 28, 706-716.	2.0	43
50	EMAS position statement: Managing the menopause in women with a past history of endometriosis. <i>Maturitas</i> , 2010, 67, 94-97.	2.4	42
51	Osteoporosis management in patients with breast cancer: EMAS position statement. <i>Maturitas</i> , 2017, 95, 65-71.	2.4	42
52	EMAS recommendations for conditions in the workplace for menopausal women. <i>Maturitas</i> , 2016, 85, 79-81.	2.4	40
53	Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1787-1797.	7.9	40
54	Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. <i>Maturitas</i> , 2020, 135, 74-79.	2.4	40

#	ARTICLE	IF	CITATIONS
55	EMAS position statement: Diet and health in midlife and beyond. <i>Maturitas</i> , 2013, 74, 99-104.	2.4	39
56	The Mediterranean diet and menopausal health: An EMAS position statement. <i>Maturitas</i> , 2020, 139, 90-97.	2.4	39
57	Polycystic Ovary Syndrome in Adolescents. <i>Paediatric Drugs</i> , 2006, 8, 311-318.	3.1	38
58	A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. <i>Maturitas</i> , 2006, 53, 413-423.	2.4	38
59	EMAS position statement: Managing menopausal women with a personal or family history of VTE. <i>Maturitas</i> , 2011, 69, 195-198.	2.4	38
60	Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype. <i>Journal of Hypertension</i> , 2013, 31, 1998-2004.	0.5	38
61	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. <i>Maturitas</i> , 2020, 131, 91-101.	2.4	37
62	The Cardiovascular Effects of Selective Estrogen Receptor Modulators. <i>Annals of the New York Academy of Sciences</i> , 2006, 1092, 374-384.	3.8	36
63	Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A <sub>1</sub> , apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. <i>Gynecological Endocrinology</i> , 2004, 18, 244-257.	1.7	35
64	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. <i>Maturitas</i> , 2021, 148, 55-61.	2.4	35
65	Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels. <i>Gynecological Endocrinology</i> , 2005, 20, 227-235.	1.7	34
66	Free androgen index as a predictor of blood pressure progression and accelerated vascular aging in menopause. <i>Atherosclerosis</i> , 2016, 247, 177-183.	0.8	34
67	Bone Health in Patients with Dyslipidemias: An Underestimated Aspect. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1639.	4.1	34
68	Body composition changes in chronic hemodialysis patients before and after hemodialysis as assessed by dual-energy x-ray absorptiometry. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 1059-1062.	3.4	33
69	Arterial Wave Reflections During the Menstrual Cycle of Healthy Women. <i>Hypertension</i> , 2009, 54, 1021-1027.	2.7	33
70	Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. <i>International Journal of Cardiology</i> , 2013, 164, 70-76.	1.7	33
71	EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. <i>Maturitas</i> , 2013, 74, 279-282.	2.4	33
72	Increased Maternal Serum Interleukin-6 Concentrations at 11 to 14 Weeks of Gestation in Low Risk Pregnancies Complicated with Gestational Diabetes Mellitus: Development of a Prediction Model. <i>Hormone and Metabolic Research</i> , 2016, 48, 35-41.	1.5	33

#	ARTICLE	IF	CITATIONS
73	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. <i>Maturitas</i> , 2022, 163, 1-14.	2.4	33
74	Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. <i>Climacteric</i> , 2012, 15, 350-357.	2.4	32
75	Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	1.5	32
76	How we treat endocrine complications of immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100011.	4.5	32
77	Additive effect of depressed mood and vasomotor symptoms on postmenopausal insomnia. <i>Menopause</i> , 2009, 16, 837-842.	2.0	31
78	Determinants of quality of life in Greek middle-age women: A population survey. <i>Maturitas</i> , 2012, 71, 154-161.	2.4	31
79	Vasomotor and depression symptoms may be associated with different sleep disturbance patterns in postmenopausal women. <i>Menopause</i> , 2015, 22, 1053-1057.	2.0	31
80	Androgens associated with advanced glycation end-products in postmenopausal women. <i>Menopause</i> , 2010, 17, 1182-1187.	2.0	30
81	Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. <i>International Journal of Clinical Practice</i> , 2016, 70, 967-977.	1.7	30
82	The Impact of Obesity on the Association between Vitamin D Deficiency and Cardiovascular Disease. <i>Nutrients</i> , 2019, 11, 2458.	4.1	30
83	Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101561.	4.7	30
84	Diabetes in Menopause: Risks and Management. <i>Current Vascular Pharmacology</i> , 2019, 17, 556-563.	1.7	30
85	Stress urinary incontinence and endogenous sex steroids in postmenopausal women. <i>Neurourology and Urodynamics</i> , 2017, 36, 121-125.	1.5	29
86	Vitamin D and cardiovascular disease. <i>Maturitas</i> , 2018, 115, 1-22.	2.4	29
87	Pathophysiology of bone loss in the female athlete. <i>Annals of the New York Academy of Sciences</i> , 2010, 1205, 45-50.	3.8	28
88	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. <i>Maturitas</i> , 2021, 151, 55-62.	2.4	28
89	Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. <i>Journal of Rheumatology</i> , 2000, 27, 1759-65.	2.0	28
90	Apoptosis in Atherosclerosis: A Mini-Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 912-918.	2.4	27

#	ARTICLE	IF	CITATIONS
91	Thyroid function and postpartum mood disturbances in Greek women. <i>Journal of Affective Disorders</i> , 2010, 121, 278-282.	4.1	27
92	High normal thyroid-stimulating hormone is associated with arterial stiffness in healthy postmenopausal women. <i>Journal of Hypertension</i> , 2012, 30, 592-599.	0.5	27
93	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. <i>Maturitas</i> , 2021, 143, 223-230.	2.4	27
94	Premature ovarian insufficiency: A toolkit for the primary care physician. <i>Maturitas</i> , 2021, 147, 53-63.	2.4	27
95	Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 24, 65-71.	2.7	26
96	Cardiovascular disease: Screening and management of the asymptomatic high-risk post-menopausal woman. <i>Maturitas</i> , 2005, 52, 32-37.	2.4	26
97	Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. <i>Maturitas</i> , 2018, 109, 78-80.	2.4	26
98	Bsm1 vitamin D receptor polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. <i>European Journal of Neurology</i> , 2011, 18, 93-98.	3.3	25
99	Recently postmenopausal women have the same prevalence of subclinical carotid atherosclerosis as age and traditional risk factor matched men. <i>Atherosclerosis</i> , 2012, 221, 508-513.	0.8	25
100	Can premenstrual syndrome affect arterial stiffness or blood pressure?. <i>Atherosclerosis</i> , 2012, 224, 170-176.	0.8	25
101	The interplay between diabetes mellitus and menopause: clinical implications. <i>Nature Reviews Endocrinology</i> , 2022, 18, 608-622.	9.6	25
102	Determinants of serum leptin levels in healthy postmenopausal women. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 1225-1230.	3.3	24
103	The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement. <i>Maturitas</i> , 2022, 158, 70-77.	2.4	24
104	A model of care for healthy menopause and ageing: EMAS position statement. <i>Maturitas</i> , 2016, 92, 1-6.	2.4	23
105	Androgens and cardiovascular disease in women and men. <i>Maturitas</i> , 2017, 104, 54-72.	2.4	23
106	Dietary patterns, Mediterranean diet and obesity in postmenopausal women. <i>Maturitas</i> , 2018, 110, 79-85.	2.4	23
107	Menopause-associated risk of cardiovascular disease. <i>Endocrine Connections</i> , 2022, 11, .	1.9	23
108	Body composition assessment by dual-energy X-ray absorptiometry: Comparison of prone and supine measurements. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 1379-1382.	3.4	22

#	ARTICLE	IF	CITATIONS
109	Reproductive hormones and postpartum mood disturbances in Greek women. <i>Gynecological Endocrinology</i> , 2011, 27, 543-550.	1.7	22
110	Progestogens in postmenopausal hormone therapy and the risk of breast cancer. <i>Maturitas</i> , 2014, 77, 311-317.	2.4	22
111	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	4.5	22
112	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. <i>Journal of Sexual Medicine</i> , 2019, 16, 1331-1337.	0.6	22
113	Absence of high-risk $\alpha$ 1 allele associated with osteoporosis at the intronic SP1 binding-site of collagen $\alpha$ 1 gene in Southern Chinese. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 499-502.	3.3	21
114	Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. <i>Maturitas</i> , 2005, 50, 321-330.	2.4	21
115	Hemodynamic Markers and Subclinical Atherosclerosis in Postmenopausal Women With Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2704-2711.	3.6	21
116	Determinants of Secondary Hyperparathyroidism in Bariatric Patients after Roux-en-Y Gastric Bypass or Sleeve Gastrectomy: A Pilot Study. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	1.5	21
117	Indices of adiposity and thyroid hormones in euthyroid postmenopausal women. <i>European Journal of Endocrinology</i> , 2015, 173, 237-245.	3.7	21
118	Current management of pelvic organ prolapse in aging women: EMAS clinical guide. <i>Maturitas</i> , 2018, 110, 118-123.	2.4	21
119	Cardiometabolic health in premature ovarian insufficiency. <i>Climacteric</i> , 2021, 24, 474-480.	2.4	21
120	The effect of low dose hormone therapy on mammographic breast density. <i>Maturitas</i> , 2006, 54, 78-85.	2.4	20
121	The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: A pilot study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011, 37, 1415-1422.	1.3	20
122	EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes. <i>Maturitas</i> , 2014, 79, 481-486.	2.4	20
123	Greek-origin royal jelly improves the lipid profile of postmenopausal women. <i>Gynecological Endocrinology</i> , 2016, 32, 835-839.	1.7	20
124	Therapeutic strategies for type 2 diabetes mellitus in women after menopause. <i>Maturitas</i> , 2019, 126, 69-72.	2.4	20
125	Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. <i>Maturitas</i> , 2008, 59, 62-71.	2.4	19
126	Serum lipid levels and bone mineral density in Greek postmenopausal women. <i>Gynecological Endocrinology</i> , 2012, 28, 655-660.	1.7	19



#	ARTICLE	IF	CITATIONS
127	Abnormal fasting, post-load or combined glucose values on oral glucose tolerance test and pregnancy outcomes in women with gestational diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108048.	2.8	19
128	Estrogen and bones after menopause: a reappraisal of data and future perspectives. <i>Hormones</i> , 2021, 20, 13-21.	1.9	19
129	Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. <i>Fertility and Sterility</i> , 2003, 79, 455-456.	1.0	18
130	The effect of various regimens of hormone replacement therapy on mammographic breast density. <i>Maturitas</i> , 2003, 45, 109-118.	2.4	18
131	Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. <i>Atherosclerosis</i> , 2007, 193, 142-150.	0.8	18
132	Lack of association between vitamin D levels and bone mineral density in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 313, 137-141.	0.6	18
133	The metabolic syndrome is associated with carotid atherosclerosis and arterial stiffness in asymptomatic, nondiabetic postmenopausal women. <i>Gynecological Endocrinology</i> , 2018, 34, 78-82.	1.7	18
134	Quality of life and psychological symptoms in Greek postmenopausal women: Association with hormone therapy. <i>Gynecological Endocrinology</i> , 2006, 22, 660-668.	1.7	17
135	Ovarian endometriosis associated with ovarian cancer and endometrial?endocervical polyps. <i>Journal of Obstetrics and Gynaecology Research</i> , 2007, 33, 294-298.	1.3	17
136	Methylenetetrahydrofolate reductase C677T polymorphism is associated with central adiposity and increased androgenicity in healthy postmenopausal women. <i>European Journal of Endocrinology</i> , 2008, 159, 233-241.	3.7	17
137	EMAS position statement: Bone densitometry screening for osteoporosis. <i>Maturitas</i> , 2011, 68, 98-101.	2.4	17
138	EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis. <i>Maturitas</i> , 2012, 71, 194-198.	2.4	17
139	Vitamin D receptor Bsm1 polymorphism, calcium metabolism and bone mineral density in patients with multiple sclerosis: a pilot study. <i>Neurological Sciences</i> , 2013, 34, 1433-1439.	1.9	17
140	Reply of the Authors: Endometriosis and oxidative stressâ€”serum markers?. <i>Fertility and Sterility</i> , 2008, 89, 1283.	1.0	16
141	Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- $\kappa$ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-8.	1.5	16
142	Free androgen index as a determinant of arterial stiffness in menopause: a mediation analysis. <i>Menopause</i> , 2017, 24, 635-644.	2.0	16
143	Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause. <i>Journal of Human Hypertension</i> , 2017, 31, 520-524.	2.2	16
144	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. <i>Maturitas</i> , 2017, 100, 86-91.	2.4	16

#	ARTICLE	IF	CITATIONS
145	Physical activity is associated with lower arterial stiffness in normal-weight postmenopausal women. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1682-1690.	2.0	16
146	Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. <i>Maturitas</i> , 2004, 48, 107-113.	2.4	15
147	EMAS position statement: Fertility preservation. <i>Maturitas</i> , 2014, 77, 85-89.	2.4	15
148	Turner syndrome and osteoporosis. <i>Maturitas</i> , 2019, 130, 41-49.	2.4	15
149	Maternal Prenatal Stress, Thyroid Function and Neurodevelopment of the Offspring: A Mini Review of the Literature. <i>Frontiers in Neuroscience</i> , 2021, 15, 692446.	2.8	15
150	Thyroid function and autoimmunity are associated with the risk of vertebral fractures in postmenopausal women. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 227-233.	2.7	14
151	Androgen excess and post-reproductive health. <i>Maturitas</i> , 2018, 115, 115-116.	2.4	14
152	Lactation and maternal cardiovascular disease risk in later life. <i>Maturitas</i> , 2019, 122, 73-79.	2.4	14
153	The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. <i>Menopause</i> , 2004, 11, 299-305.	2.0	13
154	Differential Effect of Hormone Therapy and Tibolone on Lipids, Lipoproteins, and the Atherogenic Index of Plasma. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 542-548.	1.9	13
155	Anti-Allerian Hormone Concentrations Are Inversely Associated With Subclinical Atherosclerosis in Premenopausal Women. <i>Angiology</i> , 2020, 71, 552-558.	1.8	13
156	The SCH9 protein kinase mRNA contains a long 5' leader with a small open reading frame. <i>Yeast</i> , 1993, 9, 21-32.	1.7	12
157	Prevalence of vasomotor, psychological, psychosomatic and sexual symptoms in perimenopausal and recently postmenopausal Greek women: association with demographic, life-style and hormonal factors. <i>Gynecological Endocrinology</i> , 2013, 29, 125-128.	1.7	12
158	Global Consensus Position Statement on the use of Testosterone Therapy for Women. <i>Maturitas</i> , 2019, 128, 89-93.	2.4	12
159	Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 375-381.	1.9	12
160	EMAS position statement: Managing the menopause in women with epilepsy. <i>Maturitas</i> , 2010, 66, 327-328.	2.4	11
161	Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 154, 141-145.	1.1	11
162	Sex Hormones in Postmenopausal Women Receiving Low-Dose Hormone Therapy: The Effect of BMI. <i>Obesity</i> , 2011, 19, 988-993.	3.0	11

#	ARTICLE	IF	CITATIONS
163	Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2017, 17, 444-449.	0.1	11
164	Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1609-1623.	3.3	11
165	Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. <i>European Journal of Endocrinology</i> , 2004, 151, 187-192.	3.7	10
166	Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. <i>Fertility and Sterility</i> , 2004, 82, 634-638.	1.0	10
167	Sp1 collagen I A1 polymorphism in women with stress urinary incontinence. <i>International Urogynecology Journal</i> , 2011, 22, 835-839.	1.4	10
168	Recommendations on the management of fragility fracture risk in women younger than 70 years. <i>Gynecological Endocrinology</i> , 2012, 28, 770-786.	1.7	10
169	Menopause in women with multiple sclerosis: A systematic review. <i>Maturitas</i> , 2020, 135, 68-73.	2.4	10
170	Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome. <i>Current Vascular Pharmacology</i> , 2019, 17, 579-590.	1.7	10
171	Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats. <i>Contraception</i> , 2005, 71, 362-371.	1.5	9
172	Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. <i>Climacteric</i> , 2008, 11, 155-165.	2.4	9
173	CYP A-204C polymorphism is associated with subclinical atherosclerosis in postmenopausal women. <i>Menopause</i> , 2008, 15, 1163-1168.	2.0	9
174	The frequency of early, spontaneous miscarriage associated with the leu33pro polymorphism of Glycoprotein IIIa: A pilot study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010, 50, 485-490.	1.0	9
175	Circulating androgens are associated with mood disturbances in young postmenopausal women. <i>Climacteric</i> , 2015, 18, 205-213.	2.4	9
176	The intensity of menopausal symptoms is associated with episodic memory in postmenopausal women. <i>Climacteric</i> , 2016, 19, 393-399.	2.4	9
177	Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. <i>Epilepsy and Behavior</i> , 2016, 55, 84-86.	1.7	9
178	EMAS position statement: Late parenthood. <i>Maturitas</i> , 2013, 76, 200-204.	2.4	8
179	Bsm1 Vitamin D Receptor Polymorphism and Calcium Homeostasis Following Bariatric Surgery. <i>Journal of Investigative Surgery</i> , 2015, 28, 8-17.	1.3	8
180	The role of total body fat mass and trunk fat mass, combined with other endocrine factors, in menstrual recovery and psychopathology of adolescents with Anorexia Nervosa. <i>Gynecological Endocrinology</i> , 2017, 33, 757-762.	1.7	8

#	ARTICLE	IF	CITATIONS
181	Bone health care in women with breast cancer. <i>Hormones</i> , 2020, 19, 171-178.	1.9	8
182	GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2287.	4.1	8
183	Effect of hormone therapy on the elastic properties of the arteries in healthy postmenopausal women. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 305-311.	3.3	7
184	The differential effect of estrogen, estrogen+progestin and tibolone on coagulation inhibitors in postmenopausal women. <i>Climacteric</i> , 2007, 10, 400-407.	2.4	7
185	Apolipoprotein E and Paraoxonase 1 polymorphisms are associated with lower serum thyroid hormones in postmenopausal women. <i>Clinical Endocrinology</i> , 2009, 71, 284-290.	2.4	7
186	EMAS position statement: Menopause for medical students. <i>Maturitas</i> , 2014, 78, 67-69.	2.4	7
187	Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density. <i>Spine Journal</i> , 2015, 15, 86-94.	1.3	7
188	Dietary patterns and cardiovascular risk in postmenopausal women: Protocol of a cross-sectional and prospective study. <i>Maturitas</i> , 2018, 116, 59-65.	2.4	7
189	Effect of oral phytoestrogens on endometrial thickness and breast density of perimenopausal and postmenopausal women: A systematic review and meta-analysis. <i>Maturitas</i> , 2019, 124, 81-88.	2.4	7
190	Association of menopausal symptoms with sociodemographic factors and personality traits. <i>Przegląd Menopauzalny</i> , 2019, 18, 191-197.	1.3	7
191	Updates on the treatment of invasive breast cancer: Quo Vadimus?. <i>Maturitas</i> , 2021, 145, 64-72.	2.4	7
192	EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. <i>Maturitas</i> , 2014, 78, 131-137.	2.4	6
193	Joint Opinion Paper- "Ageing and sexual health"™™ by the European Board & College of Obstetrics and Gynaecology (EBCOG) and the European Menopause and Andropause Society (EMAS). <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 220, 132-134.	1.1	6
194	Free Androgen Index as a Biomarker of Increased Cardiovascular Risk in Postmenopausal Women. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1986.	2.8	6
195	Diet and lifestyle for post-reproductive health: Focus on diabetes. <i>Case Reports in Women's Health</i> , 2018, 18, e00056.	0.5	6
196	Subclinical atherosclerosis and vascular stiffness in premenopausal women: association with NOS3 and CYBA polymorphisms. <i>Heart and Vessels</i> , 2018, 33, 1434-1444.	1.2	6
197	Premature ovarian insufficiency: a toolkit for the primary care physician. <i>Climacteric</i> , 2021, 24, 425-437.	2.4	6
198	Authors' reply: Communicating evidence-based practice in menopause. <i>Nature Reviews Disease Primers</i> , 2015, 1, .	30.5	5

#	ARTICLE	IF	CITATIONS
199	Maternal serum osteocalcin at 11–14 weeks of gestation in gestational diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1025-1031.	3.4	5
200	Endogenous sex hormones and memory performance in middle-aged Greek women with subjective memory complaints. <i>Neurological Sciences</i> , 2018, 39, 259-266.	1.9	5
201	Abdominal Fat Tissue Echogenicity: A Marker of Morbid Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 301-311.	3.6	5
202	Circulating Amyloid Beta 1–40 Is Associated with Increased Rate of Progression of Atherosclerosis in Menopause: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 650-658.	3.4	5
203	Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 521-6.	3.3	5
204	The effect of hormone therapy on biochemical and ultrasound parameters associated with atherosclerosis in 46,XY DSD individuals with female phenotype. <i>Gynecological Endocrinology</i> , 2014, 30, 721-725.	1.7	4
205	Psychological but not vasomotor symptoms are associated with temperament and character traits. <i>Climacteric</i> , 2014, 17, 500-509.	2.4	4
206	Menopausal hormone therapy for the prevention of cardiovascular disease: Evidence-based customization. <i>Maturitas</i> , 2015, 81, 421-422.	2.4	4
207	Variations in glomerular filtration rate are associated with subclinical atherosclerosis in healthy postmenopausal women. <i>Menopause</i> , 2015, 22, 317-324.	2.0	4
208	Association of sex hormones and glucose metabolism with the severity of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2016, 126, 797-804.	1.6	4
209	Menopause: Women should not suffer in silence. <i>Maturitas</i> , 2019, 124, 91-92.	2.4	4
210	Predictors of incident hypertension in healthy non-diabetic postmenopausal women with normal renal function. <i>Gynecological Endocrinology</i> , 2019, 35, 1063-1066.	1.7	4
211	Menopausal hormone therapy and breast cancer risk: All progestogens are not the same. <i>Case Reports in Women's Health</i> , 2021, 29, e00270.	0.5	4
212	Serum lipids and apolipoproteins in Greek postmenopausal women: Association with estrogen, estrogen-progestin, tibolone and raloxifene therapy. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 545-551.	3.3	3
213	Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. <i>Climacteric</i> , 2009, 12, 240-247.	2.4	3
214	Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women. <i>Climacteric</i> , 2013, 16, 258-264.	2.4	3
215	On the use and abuse of register studies: The case of menopausal hormone therapy. <i>Maturitas</i> , 2019, 123, 91-92.	2.4	3
216	Management of dyslipidaemias in the elderly population—A narrative review. <i>Maturitas</i> , 2019, 124, 93-99.	2.4	3

#	ARTICLE	IF	CITATIONS
217	Menopausal hormone therapy and breast cancer: Need to put risks in perspective. <i>Maturitas</i> , 2020, 131, 89-90.	2.4	3
218	Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety. <i>Maturitas</i> , 2020, 141, 85-86.	2.4	3
219	Menopausal hormone therapy for women with obesity in the era of COVID-19. <i>Case Reports in Women's Health</i> , 2020, 27, e00233.	0.5	3
220	Breastfeeding is associated with lower subclinical atherosclerosis in postmenopausal women. <i>Gynecological Endocrinology</i> , 2020, 36, 796-799.	1.7	3
221	Assessing the efficacy of a structured stress management program in reducing stress and climacteric symptoms in peri- and postmenopausal women. <i>Archives of Women's Mental Health</i> , 2021, 24, 727-735.	2.6	3
222	Does reproductive stage impact cardiovascular disease risk factors? Results from a population-based cohort in Lausanne (CoLaus study). <i>Clinical Endocrinology</i> , 2022, 97, 568-580.	2.4	3
223	E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene. <i>Fertility and Sterility</i> , 2008, 89, 1018-1020.	1.0	2
224	Irritability in Menopause: An Investigation of Its Relation to Menopausal, Hormonal and Physical Factors. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 128-130.	8.8	2
225	Expression of gonadal steroid receptors in the ovaries of post-menopausal women with malignant or benign endometrial pathology: a pilot study. <i>Gynecological Endocrinology</i> , 2015, 31, 613-617.	1.7	2
226	“Holidays” for osteoporosis drugs: A case-based approach. <i>Case Reports in Women's Health</i> , 2019, 23, e00127.	0.5	2
227	Retinol-binding protein 4 is associated with arterial stiffness in early postmenopausal women. <i>Menopause</i> , 2020, 27, 906-912.	2.0	2
228	Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2010, 94, 2399-2401.	1.0	1
229	Erratum to “EMAS position statement: Bone densitometry screening for osteoporosis” [ <i>Maturitas</i> 68 (2011) 98-101]. <i>Maturitas</i> , 2011, 69, e5.	2.4	1
230	Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells?. <i>Climacteric</i> , 2012, 15, 181-185.	2.4	1
231	Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?. <i>Maturitas</i> , 2013, 74, 107-108.	2.4	1
232	MTHFR C677T polymorphism modifies the effect of HRT on metabolic parameters in postmenopausal women. <i>Climacteric</i> , 2013, 16, 568-575.	2.4	1
233	Predictors of incident hypertension in postmenopausal women: A pilot study. <i>Maturitas</i> , 2015, 81, 144.	2.4	1
234	A case of postmenopausal androgen excess. <i>Gynecological Endocrinology</i> , 2015, 31, 760-764.	1.7	1

#	ARTICLE	IF	CITATIONS
235	Menopause and its metabolic implications. <i>Maturitas</i> , 2017, 100, 102.	2.4	1
236	Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. <i>Maturitas</i> , 2017, 100, 156.	2.4	1
237	Bisphosphonate and denosumab "holiday" in postmenopausal osteoporosis: A systematic review of randomized-controlled trials. <i>Maturitas</i> , 2017, 100, 140.	2.4	1
238	Metabolic Syndrome and Atherosclerosis in Nondiabetic Postmenopausal Women. , 2019, , 237-248.		1
239	Drug holidays in osteoporosis treatment: mind the gaps!. <i>Osteoporosis International</i> , 2019, 30, 2523-2524.	3.1	1
240	Incident hypertension after menopause is mostly associated with obesity and insulin resistance. <i>Maturitas</i> , 2019, 124, 139.	2.4	1
241	Breast cancer risk and hormone replacement therapy: Whether "absolute" or "relative", the conundrum remains. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 244, 190-191.	1.1	1
242	Antipsychotic therapies and bone health. <i>Case Reports in Women's Health</i> , 2020, 25, e00160.	0.5	1
243	Serum prolactin levels interact with menstrual fluctuations of arterial stiffness. <i>Hellenic Journal of Cardiology</i> , 2021, 63, 89-89.	1.0	1
244	Polycystic Ovary Syndrome-Related Risks in Postmenopausal Women. , 2019, , 249-259.		1
245	Ovarian volume is associated with adiposity measures and bone mineral density in postmenopausal women. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2018, 18, 501-508.	0.1	1
246	Hormone therapy for menopause and premature ovarian insufficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101597.	4.7	1
247	Endothelial Function in Postmenopausal Women: The Possible Role of Heat Shock Protein 60 and Serum Androgens. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	1.9	1
248	Parity is associated with lower cervical E-cadherin expression in postmenopausal women. <i>Journal of Obstetrics and Gynaecology Research</i> , 2008, 34, 1043-1048.	1.3	0
249	P832 Association of endogenous androgens with vascular markers of early atherosclerosis in healthy postmenopausal women. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 107, S648.	2.3	0
250	The effect of hormone therapy and tibolone on serum CD40L and ADAM-8 in healthy post-menopausal women. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 720-724.	3.3	0
251	Hormones in the immediate postpartum period as a risk factor for postnatal depression, at two months postpartum. <i>European Psychiatry</i> , 2011, 26, 594-594.	0.2	0
252	Erratum to "EMAS position statement: Managing obese postmenopausal women" [ <i>Maturitas</i> 66 (2010) 323-326]. <i>Maturitas</i> , 2011, 69, e2.	2.4	0



#	ARTICLE	IF	CITATIONS
253	Erratum to "EMAS position statement: Managing the menopause in women with epilepsy" [Maturitas 66 (2010) 327-328]. Maturitas, 2011, 69, e3.	2.4	0
254	Erratum to "EMAS position statement: Managing women with premature ovarian failure" [Maturitas 67 (2010) 91-93]. Maturitas, 2011, 69, e4.	2.4	0
255	Erratum to "EMAS position statement: Managing the menopause in the context of coronary heart disease" [Maturitas 68 (2011) 94-97]. Maturitas, 2011, 69, e6.	2.4	0
256	Non-Hemodynamic Components of EVA. , 2015, , 181-194.		0
257	Glomerular filtration rate is associated with subclinical atherosclerosis in healthy postmenopausal women. Maturitas, 2015, 81, 133.	2.4	0
258	Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters and bone mineral density. Maturitas, 2015, 81, 143.	2.4	0
259	Premenstrual syndrome and arterial stiffness. Maturitas, 2015, 81, 134.	2.4	0
260	Non-hormonal management of menopausal vasomotor symptoms: Psychosocial interventions. Maturitas, 2015, 82, 444-445.	2.4	0
261	Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.. Maturitas, 2017, 102, 76-77.	2.4	0
262	Vasomotor symptoms are associated with episodic memory in postmenopausal women. Maturitas, 2017, 100, 187-188.	2.4	0
263	Parathyroid hormone levels in menopause: Associations with demographic characteristics, calcium supplementation and sex hormone profile. Maturitas, 2017, 100, 124-125.	2.4	0
264	Calcium metabolism in relation to subclinical arterial stiffness in asymptomatic, non-diabetic postmenopausal women. Maturitas, 2017, 100, 126.	2.4	0
265	The TyG index: a novel marker of subclinical atherosclerosis and arterial stiffness in lean postmenopausal women. Maturitas, 2017, 100, 202.	2.4	0
266	Menopause Hormone Therapy Customization. ISGE Series, 2018, , 253-259.	0.2	0
267	Weight and Body Composition Management After Menopause: The Effect of Lifestyle Modifications. ISGE Series, 2018, , 153-161.	0.2	0
268	Management of stress and anxiety during the menopausal transition: effect on climacteric symptoms in a Greek peri- and postmenopausal population. Maturitas, 2019, 124, 160.	2.4	0
269	Higher levels of circulating androgens are associated with greater extent of liver fibrosis in postmenopausal women. Maturitas, 2019, 124, 157-158.	2.4	0
270	Presence of the methylenetetrahydrofolate reductase A1298T polymorphism is associated with lower body mass index in girls with anorexia nervosa. Maturitas, 2019, 124, 156.	2.4	0



#	ARTICLE	IF	CITATIONS
271	Subcutaneous fat tissue echogenicity: a marker of subclinical atherosclerosis. <i>Maturitas</i> , 2019, 124, 144-145.	2.4	0
272	Dietary patterns are associated with aortic stiffness and carotid artery intima-media thickness in healthy postmenopausal women. <i>Maturitas</i> , 2019, 124, 161-162.	2.4	0
273	Anthropometric predictors of metabolic health in postmenopausal women with normal weight. <i>Maturitas</i> , 2019, 124, 155.	2.4	0
274	Treating hypothyroidism in people over 70. <i>Maturitas</i> , 2020, 136, 60.	2.4	0
275	Reproductive variables and subclinical vascular disease. <i>Gynecological Endocrinology</i> , 2020, 36, 941-942.	1.7	0
276	MTHFR Polymorphisms in Girls with Anorexia Nervosa: Implications on Body Weight. <i>Endocrine Research</i> , 2021, 46, 80-85.	1.2	0
277	Does transition through menopause affect cardiovascular disease risk factors? Results from a population-based cohort (CoLaus study). <i>European Heart Journal</i> , 2021, 42, .	2.2	0
278	The severity of menopausal symptoms is associated with the presence of diabetes mellitus and adiposity. <i>Maturitas</i> , 2021, 152, 78.	2.4	0
279	Circulating levels of Amyloid Beta 1-40 are associated with the rate of progression of atherosclerosis in menopause. <i>Maturitas</i> , 2021, 152, 95.	2.4	0
280	Long-term health in women of age more than 40 years with polycystic ovary syndrome. , 2022, , 245-285.		0
281	Menstrual irregularity and bone health in premenopausal women: Are oral contraceptives the best option?. <i>Maturitas</i> , 2022, 155, 70-71.	2.4	0
282	Management of steroid-induced osteoporosis. <i>Chinese Medical Journal</i> , 2000, 113, 681-5.	2.3	0
283	Endometriosis and other benign and malignant allergic lesions in pelvic and extrapelvic organs. , 2009, 31, 170-6.		0